Company: RCUS
Filing Date: 2025-02-18
Form Type: 424B5
Source: 0001193125-25-028669
Chunk: 42

Company: Arcus Biosciences, Inc.
Filing Date: 2025-02-18
Form: 424B5
Chunk 42
---
 we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable:

| • |     | designation or classification; |

| • |     | aggregate principal amount or aggregate offering price; |

| • |     | maturity date, if applicable; |

2

| • |     | original issue discount, if any; |

| • |     | rates and times of payment of interest or dividends, if any; |

| • |     | redemption, conversion, exercise, exchange or sinking fund terms, if any; |

| • |     | conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments              
 in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange; |

| • |     | ranking; |

| • |     | restrictive covenants, if any; |

| • |     | voting or other rights, if any; and |

| • |     | material or special U.S. federal income tax considerations, if any. |

The applicable prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change any of the information contained in this prospectus or in the documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part. THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT. We may sell the securities directly to investors or to or through agents, underwriters or dealers. We and our agents or underwriters, reserve the right to accept or reject all or part of any proposed purchase of securities. If we do offer securities to or through agents or underwriters, we will include in the applicable prospectus supplement:

| • |     | the names of those agents or underwriters; |

| • |     | applicable fees, discounts and commissions to be paid to them; |

| • |     | details regarding options to purchase additional shares, if any; and |

| • |     | the net proceeds to us. |

Common Stock. We may issue